Polymorphs of phenyl pyrrole aminoguandium salts

A method of treating a disease or disorder that is an arthritic disease, a kidney disease, a cardiovascular disease, atherosclerosis, a viral disease or disorder, or a systemic inflammatory disorder in a subject in need thereof, said method comprising administering a crystalline Form of the N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salt to the subject, wherein the crystalline Form of the N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salt is:

• i. a crystalline Form A of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium acetate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 11.5±0.2, 23.5±0.2, and 27.0±0.2,
• ii. a crystalline Form B of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium succinate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 9.7±0.2, 22.8±0.2, and 26.7±0.2,
• iii. a crystalline Form C of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium tosylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 14.5±0.2, 21.0±0.2, and 25.2±0.2,
• iv. a crystalline Form D of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium fumarate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 17.6±0.2, 21.2±0.2, and 26.3±0.2,
• v. a crystalline Form I of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium acetate exhibiting X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 23.5±0.2, 24.2±0.2, and 26.9±0.2,
• vi. a crystalline Form II of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium exhibiting X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 13.3±0.2, 21.1±0.2, and 23.1±0.2,
• vii. a crystalline Form III of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium napadisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 13.4±0.2, 22.2±0.2, and 26.8±0.2,
• viii. a crystalline Form IV of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium napadisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 5.4±0.2, 15.6±0.2, and 23.4±0.2,
• ix. a crystalline Form V of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium esylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 14.5±0.2, 16.5±0.2, and 18.6±0.2,
• x. a crystalline Form VI of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium edisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 4.8±0.2, 12.8±0.2, and 16.5±0.2,
• xi. a crystalline Form VII of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium edisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 6.1±0.2, 15.7±0.2, and 23.6±0.2,
• xii. a crystalline Form VIII of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium edisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 15.5±0.2, 20.7±0.2, and 21.7±0.2,
• xiii. a crystalline Form IX of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium edisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 4.5±0.2, 16.7±0.2, and 24.7±0.2,
• xiv. a crystalline Form X of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl 1-allylidene}-aminoguanidinium nitrate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 15.3±0.2, 21.4±0.2, and 25.1±0.2,
• xv. a crystalline Form XI of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium cyclamate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 7.0±0.2, 13.8±0.2, and 15.7±0.2,
• xvi. a crystalline Form XII of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium cyclamate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 7.3±0.2, 15.3±0.2, and 17.9±0.2,
• xvii. a crystalline Form XIII of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium cyclamate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 15.3±0.2, 18.5±0.2, and 18.7±0.2,
• xviii. a crystalline Form XIV of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium besylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 13.0±0.2, 15.1±0.2, and 19.9±0.2,
• xix. a crystalline Form XV of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium oxalate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 19.5±0.2, 23.3±0.2, and 25.8±0.2,
• xx. a crystalline Form XVI of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium oxalate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 17.1±0.2, 17.9±0.2, and 19.6±0.2,
• xxi. a crystalline Form XVII of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium oxalate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 6.3±0.2, 10.6±0.2, and 19.8±0.2,
• xxii. a crystalline Form XVIII of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidine (+)-camphor-10-sulfonic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 6.5±0.2, 11.5±0.2, and 14.8±0.2,
• xxiii. a crystalline Form XIX of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium oxoglutarate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 16.8±0.2, 23.4±0.2, and 23.6±0.2,
• xxiv. a crystalline Form XX of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidine DL-mandelic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 14.8±0.2, 24.2±0.2, and 25.5±0.2,
• xxv. a crystalline Form XXI of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidine DL-mandelic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 5.4±0.2, 10.0±0.2, and 24.6±0.2,
• xxvi. a crystalline Form XXII of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidine hippuric acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 20.1±0.2, 24.1±0.2, and 24.5±0.2,
• xxvii. a crystalline Form XXIII of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium formate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 13.3±0.2, 15.1±0.2, and 25.6±0.2,
• xxviii. a crystalline Form XXIV of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidine L-lactic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 3.8±0.2, 9.9±0.2, and 11.9±0.2,
• xxix. a crystalline Form XXV of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidine DL-lactic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 9.8±0.2, 11.9±0.2, and 27.6±0.2,
• xxx. a crystalline Form XXVI of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidine glutaric acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 8.3±0.2, 15.9±0.2, and 21.9±0.2,
• xxxi. a crystalline Form XXVII of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidine glutaric acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation selected from the group consisting of 16.9±0.2, 25.6±0.2, 27.1±0.2, 28.2±0.2, and 28.7±0.2,
• xxxii. a crystalline Form XXVIII of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidine glutaric acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 14.2±0.2, 16.9±0.2, and 24.5±0.2, or
• xxxiii. a crystalline Form XXIX of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidine adipic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 13.4±0.2, 14.5±0.2, and 25.5±0.2.